References
Avau B, Van Remoortel H, Laermans J, Bekkering G, Fergusson D, Georgsen J, et al. Lack of cost-effectiveness of preoperative erythropoiesis-stimulating agents and/or iron therapy in anaemic, elective surgery patients: a systematic review and updated analysis. Pharmacoeconomics. 2021. https://doi.org/10.1007/s40273-021-01044-3.
Coyle D, Lee KM, Fergusson DA, Laupacis A. Economic analysis of erythropoietin use in orthopaedic surgery. Transfus Med. 1999;9(1):21–30.
Coyle D, Lee KM, Fergusson DA, Laupacis A. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics. 2000;18(2):161–71.
Craig J, Brown H, Eastgate J, Macpherson K, Wilson S. In: The use of epoetin alfa before orthopaedic surgery in patients with mild anaemia. Understanding our advice: the use of epoetin alfa before orthopaedic surgery in patients with mild anaemia. 2006 Quality Improvement Scotland.
Basora M, Pereira A, Coca M, Tio M, Lozano L. Cost-effectiveness analysis of ferric carboxymaltose in pre-operative haemoglobin optimisation in patients undergoing primary knee arthroplasty. Blood Transfus. 2018;16(5):438–42.
Trentino KM, Mace HS, Symons K, Sanfilippo FM, Leahy MF, Farmer SL, et al. Screening and treating pre-operative anaemia and suboptimal iron stores in elective colorectal surgery: a cost effectiveness analysis. Anaesthesia. 2020. https://doi.org/10.1111/anae.15240.
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This manuscript received no funding.
Conflicts of interest
Mr. Trentino and Dr. Mace have nothing to disclose. Dr. Hofmann reports personal fees and non-financial support from Celgene, Belgium, personal fees and non-financial support from G1 Therapeutics, non-financial support from South African National Blood Service, South Africa, personal fees and non-financial support from Takeda, South Africa, personal fees and non-financial support from TEM Innovations, Germany, personal fees and non-financial support from Vifor Pharma International AG, Switzerland, and personal fees from Vygon SA, France, outside the submitted work.
Availability of data and material
Not applicable.
Code availability
Not applicable.
Authors' contributions
Not applicable.
Rights and permissions
About this article
Cite this article
Trentino, K.M., Mace, H. & Hofmann, A. Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery. PharmacoEconomics 40, 133–135 (2022). https://doi.org/10.1007/s40273-021-01083-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40273-021-01083-w